1. Home
  2. MDWD vs DSP Comparison

MDWD vs DSP Comparison

Compare MDWD & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • DSP
  • Stock Information
  • Founded
  • MDWD 2000
  • DSP 1999
  • Country
  • MDWD Israel
  • DSP United States
  • Employees
  • MDWD N/A
  • DSP N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • DSP EDP Services
  • Sector
  • MDWD Health Care
  • DSP Technology
  • Exchange
  • MDWD Nasdaq
  • DSP Nasdaq
  • Market Cap
  • MDWD 179.1M
  • DSP 167.4M
  • IPO Year
  • MDWD 2014
  • DSP 2021
  • Fundamental
  • Price
  • MDWD $18.00
  • DSP $10.94
  • Analyst Decision
  • MDWD Strong Buy
  • DSP Strong Buy
  • Analyst Count
  • MDWD 1
  • DSP 5
  • Target Price
  • MDWD $28.00
  • DSP $11.80
  • AVG Volume (30 Days)
  • MDWD 54.1K
  • DSP 71.9K
  • Earning Date
  • MDWD 08-14-2024
  • DSP 11-04-2024
  • Dividend Yield
  • MDWD N/A
  • DSP N/A
  • EPS Growth
  • MDWD N/A
  • DSP N/A
  • EPS
  • MDWD N/A
  • DSP N/A
  • Revenue
  • MDWD $20,141,000.00
  • DSP $243,250,000.00
  • Revenue This Year
  • MDWD $30.16
  • DSP $19.71
  • Revenue Next Year
  • MDWD $18.44
  • DSP $12.84
  • P/E Ratio
  • MDWD N/A
  • DSP N/A
  • Revenue Growth
  • MDWD N/A
  • DSP 20.25
  • 52 Week Low
  • MDWD $7.45
  • DSP $4.98
  • 52 Week High
  • MDWD $24.00
  • DSP $12.36
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 56.45
  • DSP 50.26
  • Support Level
  • MDWD $17.50
  • DSP $10.50
  • Resistance Level
  • MDWD $17.90
  • DSP $11.03
  • Average True Range (ATR)
  • MDWD 0.81
  • DSP 0.37
  • MACD
  • MDWD 0.13
  • DSP 0.02
  • Stochastic Oscillator
  • MDWD 80.33
  • DSP 50.82

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.

Share on Social Networks: